---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-023644"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:56:36.870048+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Emmaus enters Exclusive Supply Agreement with NeoImmuneTech for Endari in US/Canada

## Summary
- Agreement dated March 2, 2026; Emmaus to supply Endari (L-glutamine) exclusively to NIT for sickle cell disease in US and Canada.
- Supply price is Emmaus' production cost plus a specified double-digit percentage margin.
- Effective Date contingent on NIT obtaining necessary regulatory approvals and licensing; must occur by October 1, 2026.
- Either party may terminate if Effective Date does not occur by Oct 1, 2026 (unless due to Emmaus' wrongful acts).
- Exclusive Supply Agreement is a follow-up to the License Agreement reported on December 31, 2025.

## SEC filing metadata
- accession: 0001213900-26-023644
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390026023644/0001213900-26-023644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390026023644/ea0280016-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-023644
- JSON: https://secwatch.observer/filing/0001213900-26-023644.json
- Plain text: https://secwatch.observer/filing/0001213900-26-023644.txt

## Key facts
- Material Agreements
  Emmaus Life Sciences, Inc. entered into Exclusive Supply Agreement with NeoImmuneTech, Inc. (NIT) (effective 2026-03-02).
  - Action: entry
  - Agreement: supply
  - Counterparty: NeoImmuneTech, Inc. (NIT)
  - Effective: 2026-03-02
  source text: n March 2, 2026, Emmaus and NIT entered into the Exclusive Supply Agreement contemplated by the License Agreement. Subject to the occurrence
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390026023644/0001213900-26-023644-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.